GH Research PLC (NASDAQ: GHRS) announced the publication of its Phase 2b trial results for mebufotenin (GH001) in treatment-resistant depression ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE